Print this page    •   Back to Web version of article

Integrase Inhibitor '572 Tested Against Raltegravir-Resistant HIV

By Sean R. Hosein

October 25, 2010

GlaxoSmithKline (GSK) has licensed an anti-HIV integrase inhibitor discovered by the Shionogi Corporation in Japan. Because of these arrangements, this drug has the complex code name S/GSK1349572 and for now is increasingly referred to simply as '572 by researchers.

In lab experiments '572 has activity against HIV that is resistant to raltegravir, the only currently approved integrase inhibitor.

Researchers tested '572 in HIV-positive volunteers who had HIV that was resistant to raltegravir. Participants either substituted '572 in place of raltegravir or started taking '572 if they had already quit raltegravir. All participants had HIV that was also resistant to drugs from the three commonly used groups of anti-HIV medicines:

For the first 11 days of the study, participants received 50 mg once daily of '572 and no other drugs. After this period they also received an optimized background regimen based on resistance testing and medical history. This study is called Viking and so far only results from the first 11 days have been released.

The average profile of the 27 participants enrolled at the start of the study was as follows:

Examples of prior ART used included these drugs, which were used by the following proportion of participants:

That most of these potent drugs were commonly used suggests that the study group represented heavily pre-treated patients.


Results

After 11 days, 21 out of 27 participants (78%) had their viral load fall to 400 copies/ml or less or had their viral load fall by 0.7 log.


Side Effects

Participants in this study had weak immune systems and sometimes it is difficult to separate drug side effects from symptoms of HIV disease in this population. Despite this, investigators determined that the following side effects were caused by '572:

Two participants had severely elevated levels of pancreatic enzymes; it is not yet certain if this is due to exposure to '572. However, no serious or life-threatening complications occurred after exposure to '572.

Long-term results from Viking are needed to assess the benefit of '572 in raltegravir-resistant people.


Reference

  1. Eron J, Durant J, Poizot-Martin I, et al. Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). In: Program and abstracts of the 18th International Conference on AIDS, 18-23 July 2010, Vienna, Austria. Abstract MOAB0105.




This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication Treatment Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art59254.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.